Brief Description:

The test combines two patented multiplexed cancer diagnostic technologies: visualization (RNA FISH) and RNA sequencing. MultiplexDX‘s IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization, and gene expression with a single-cell resolution by combining our proprietary visual and sequencing technologies into one diagnostic test. Physicians and patients will receive a clear, concise, and explainable report containing the following:

• Information about the spatial mRNA expression of the four clinical breast cancer biomarkers (Estrogen/Progesterone/Her2 receptors and Ki-67)

• Cross validated using two independent techniques: RNA FISH and RNA-seq

• Molecular subtype of breast cancer based on spatially resolved, tumor-enriched LCM-seq

• A risk score that provides the physician with a guide for tailored treatment

‍

State of development:

2022: End of retrospective clinical validation

2023: Start of prospective clinical validation

‍

‍